$XBI $154.13 (-0.09%) 📉
COVID:
$PFE (-0.65%) & $BNTX (-1.40%) - Pfizer and BioNTech Publish Results of Study Showing COVID-19 Vaccine Elicits Antibodies that Neutralize Pseudovirus Bearing the SARS-CoV-2 U.K. Strain Spike Protein in Cell Culture
$GRTS (+14.46%) - Gritstone and Genevant Sciences Announce License Agreement for COVID-19 Vaccine
PIPELINE:
$OCUL (-0.85%) - OCULAR THERAPEUTIX™ PRESENTS INTERIM TOPLINE DATA FROM THE PHASE 1 CLINICAL TRIAL OF OTX-TIC IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION AT THE 10TH ANNUAL GLAUCOMA 360 NEW HORIZONS FORUM
$AZN (-0.63%) - EU approval
$ARQT (-1.78%) - Arcutis to Advance Topical Roflumilast Foam (ARQ-154) into Phase 3 Development for the Treatment of Seborrheic Dermatitis
$ONCR (-5.00%) - ONCORUS ANNOUNCES PUBLICATION OF PRECLINICAL DATA DEMONSTRATING POTENT SYSTEMIC ANTITUMOR ACTIVITY OF ITS CLINICAL STAGE ONCOLYTIC HERPES SIMPLEX VIRAL IMMUNOTHERAPY PRODUCT CANDIDATE ONCR-177
FMTX (-2.11%) - Forma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating FT-7051 for the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC)
FINANCIAL:
$TCRR (-2.85%) - Announced the pricing of an underwritten public offering of 4,590,164 shares of its common stock at a public offering price of $30.50 per share.
$ONCS (-5.11) - OncoSec Medical Announces Proposed Public Offering of Common Stock
$ACRX (-17.02%) - AcelRx Announces Pricing of $27.5 Million Public Offering of Common Stock
$ACRS (-4.57%) - Pricing of its underwritten public offering of 5,483,714 shares of its common stock at a price to the public of $17.50 per share.
$SYRS (-11.97%) - Priced an underwritten public offering of 5,400,000 shares of common stock at a public offering price of $14.00 per share https://ir.syros.com/press-releases/detail/212/syros-announces-pricing-of-75-6-million-public-offering-of
$FULC (+18.93%) - Priced an underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $11.00 per share